Non-small cell lung cancer (NSCLC) Clinical Trials in Boston, MA
As of July 2026, 65 paid clinical trials are recruiting for Non-small cell lung cancer (NSCLC) in Boston, Massachusetts. Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Related specialties in Boston
Filter results
65 clinical trials for Non-small cell lung cancer (NSCLC)
·Clear filters·↓ Download CSVBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
A Study of LY4175408 in Participants With Advanced Cancer
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
About research studies in Boston
Boston has approximately 2,875 recruiting research studies across a wide range of therapeutic areas. Massachusetts is a global epicenter of biomedical research, anchored by Harvard-affiliated hospitals (MGH, Brigham and Women's, Dana-Farber), Boston Children's Hospital, and the Kendall Square biotech corridor in Cambridge.
Top Research Study Locations in Boston
Researchers run research studies in Boston, MA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Massachusetts General Hospital | Breast Cancer, Heart Failure, Colorectal Cancer | 691 |
| Brigham and Women's Hospital | Breast Cancer, Obesity, Prostate Cancer | 347 |
| Dana-Farber Cancer Institute | Breast Cancer, Acute Myeloid Leukemia, Multiple Myeloma | 343 |
| Beth Israel Deaconess Medical Center | Multiple Myeloma, Acute Myeloid Leukemia, Breast Cancer | 266 |
| Boston Children's Hospital | Congenital Heart Disease, Cystic Fibrosis, Sickle Cell Disease | 259 |
| Dana Farber Cancer Institute | Breast Cancer, Ovarian Cancer, Prostate Cancer | 221 |
| Tufts Medical Center | Heart Failure, Acute Myeloid Leukemia, Acute Respiratory Distress Syndrome | 107 |
| Boston Medical Center | Amblyopia, Alpha1-Antitrypsin Deficiency, Anatomic Stage II Breast Cancer AJCC v8 | 94 |
| Massachusetts General Hospital Cancer Center | Breast Cancer, Coping Skills, B Acute Lymphoblastic Leukemia | 57 |
| VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA | Chronic Obstructive Pulmonary Disease, Mild Traumatic Brain Injury, Prostate Cancer | 28 |
| Boston University | Gulf War Illness, Gulf War Syndrome, Obsessive-Compulsive Disorder | 26 |
| Brigham & Women's Hospital | Attention, Chronic Lymphocytic Leukemia, Critical Illness | 26 |
| Joslin Diabetes Center | Type 1 Diabetes Mellitus, Type 1 Diabetes (T1D), Diabetes Mellitus, Type 1 | 22 |
| Mass General Brigham | Heart Failure, Heart Failure With Preserved Ejection Fraction, Advanced Solid Tumors | 22 |
| Northeastern University | Cognitive Change, Healthy, Adults Without Language Disorder | 20 |
| Massachusetts Eye and Ear | Cone Rod Dystrophy, Glaucoma, Juvenile Macular Degeneration | 16 |
| Massachusetts Eye and Ear Infirmary | Laryngeal Dystonia, Stargardt Disease, Age-related Macular Degeneration | 13 |
| Clinical Trial Site | Transthyretin Amyloidosis With Cardiomyopathy, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency | 12 |
| Brigham and Womens Hospital | Advanced Prostate Cancer, Alpha1-Antitrypsin Deficiency, Alzheimers Disease | 12 |
| Ophthalmic Consultants of Boston | Macular Edema Secondary to Inflammation, Neovascular Age-related Macular Degeneration, AMD | 12 |
| Adams Clinical Boston | Major Depressive Disorder, Alcohol Use Disorder, Alzheimers Disease | 11 |
| Boston Childrens Hospital | CSTB-related Disease, Crohn's Disease, Cystic Fibrosis | 10 |
| Mass General Hospital | AML, Acute Lower Limb Arterial Occlusion, Advanced Cancer | 10 |
| Beth Israel Deaconess Medical Center (BIDMC) | Prostate Cancer, Advanced Melanoma, Endometrial Cancer | 9 |
| Massachusetts General Hospital (MGH) | 4H Syndrome, ADLD, AGS | 9 |
Active & Upcoming Studies in Boston (2026)
Recruiting trials in Boston grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (869 active studies)
- Early Intervention · Massachusetts General Hospital
- Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization · University of Colorado, Denver
Neurology & pain (219 active studies)
- Mindfulness Therapy for Chronic Pain After Intimate Partner Violence · Brigham and Women's Hospital
- Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · Brigham and Women's Hospital
Cardiovascular (182 active studies)
- Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · Brigham and Women's Hospital
- Boston Medical Center Ultrasound Decongestion Study in Heart Failure · Boston Medical Center
Diabetes & metabolic (97 active studies)
- Adiposity Distribution in Acute Respiratory Failure · Maurizio F. Cereda, MD
- Creating Linked Inpatient CGM for Kids · Boston Children's Hospital
Mental health & behavior (90 active studies)
- The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · Duke University
- Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study) · Phase 4 · Massachusetts General Hospital
Pediatric (60 active studies)
- B7-H3.CD28Z.CART in CNS Neoplasms · Phase 1 · Robbie Majzner
- Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study · Phase 3 · Boston Children's Hospital
HIV / STI (37 active studies)
- Intervention to Reduce Implicit Bias in Pharmacies · Massachusetts General Hospital
- Academic Detailing to Optimize PrEP Implementation in Pediatric Primary Care Settings: ADOPT-PrEP · Boston Children's Hospital
Eye & vision (31 active studies)
- Study of Remimazolam for Cataract Surgery · Phase 4 · Fred E, Shapiro
- Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema · Phase 2 · Massachusetts Eye and Ear Infirmary
Vaccines (15 active studies)
- Sauna for Long Covid · Massachusetts General Hospital
- A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID)
Common conditions studied in Boston
- Breast Cancer (64 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Prostate Cancer (39 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Heart Failure (34 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Acute Myeloid Leukemia (33 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- Ovarian Cancer (33 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Advanced Solid Tumor (32 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Boston
- Massachusetts General Hospital
- Brigham and Women's Hospital
- Boston Children's Hospital
- Dana-Farber Cancer Institute
- Beth Israel Deaconess Medical Center
Local regulations and guidelines
Clinical trials in Massachusetts are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Massachusetts trials follow additional state privacy requirements enforced under 201 CMR 17.00 and oversight from the Massachusetts Department of Public Health.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Boston. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Boston
Hipa.ai aggregates every recruiting study in Boston from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Boston?
There are approximately 2,875 recruiting clinical trials in Boston, Massachusetts listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Boston pay participants?
Most recruiting trials in Boston compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Boston?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Boston?
The most common conditions under active study in Boston include Breast Cancer (64), Prostate Cancer (39), Heart Failure (34), Acute Myeloid Leukemia (33), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Boston?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Boston on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Boston?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Boston?
Recruiting research sites in Boston include Massachusetts General Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Boston right now?
The largest active categories in Boston are Cancer & tumors (869), Neurology & pain (219), Cardiovascular (182). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.